facing_the_challenge_one_year_on

facing_the_challenge_one_year_on - FACING THE CHALLENGE ONE...

Info iconThis preview shows pages 1–6. Sign up to view the full content.

View Full Document Right Arrow Icon

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon

Info iconThis preview has intentionally blurred sections. Sign up to view the full version.

View Full DocumentRight Arrow Icon
This is the end of the preview. Sign up to access the rest of the document.

Unformatted text preview: FACING THE CHALLENGE ONE YEAR ON A progress report on our contribution to improving healthcare in the developing world CHAD COM OROS DJIBOUTI ERITRE ISSA KIRIBATI 02 FACING THE CHALLENGE ONE YEAR ON CONTENTS 4&5 Preferential Pricing Arrangements 6&7 Research and Development 8 Community Investment 9 A Global Partnership 10 Our Commitment 11 GlaxoSmithKline Principles URUNDI CAMBODIA CAPE VERDE CENTRA IN ‘FACING THE CHALLENGE’ 1 WE PROMISED THAT WE WOULD SUPPLY OUR ANTIRETROVIRALS 2 AND ANTI-MALARIALS AT SUSTAINABLE PREFERENTIAL PRICES TO ELIGIBLE CUSTOMERS IN THE LEAST DEVELOPED COUNTRIES AND ALL SUB-SAHARAN AFRICAN COUNTRIES. THE 63 COUNTRIES IN WHICH THESE PRICES ARE AVAILABLE ARE: REA ST URUN H LES Eligible customers include the public sector, not-for-profit NGOs, aid agencies, UN agencies and international purchase funds such as the Global Fund to fight AIDS, TB and Malaria. Additionally, because of the gravity of the situation in sub-Saharan Africa, employers there who offer HIV/AIDS care and treatment directly to their staff through workplace clinics are also eligible. In addition, we will continue our existing commitment to the UN-led Accelerating Access Initiative (AAI). This involves antiretroviral medicines being available at discounted prices to participating countries. ANGOLA BANGLADESH 1 http://corp.gsk.com/community/facing_the_challenge.pdf FASO UNDI 2 GSK’s C antiret A rovirals M are: Retr B ovir (A O ZT), Ep D ivir , Co I mb A ivir , Ziagen , Agen C erase A and Tri P zivir E VERDE REPUBLIC CHAD COM OROS DJIBOUTI D A LOT HAS BEEN ACHIEVED, BUT THERE REMAINS MUCH TO DO JP GARNIER, CHIEF EXECUTIVE OFFICER, GLAXOSMITHKLINE PLC A Global Challenge PROGRESS SINCE JUNE 2001 The problem of access to healthcare in developing countries presents a unique challenge to the global community. Increased shipments of preferentially priced Combivir to the developing world by tenfold. Secured almost a hundred The problem, which is rooted in poverty, demands a significant mobilisation of resources, an unprecedented sense of urgency and a new spirit of partnership. At GlaxoSmithKline, we believe we have a vital contribution to make. In June 2001, GSK published ‘Facing the Challenge’, a document setting out our commitment and contribution to improving healthcare in the developing world. We outlined three key areas in which we would make an innovative, responsible and, above all, sustainable contribution: preferential pricing on our antiretrovirals (ARVs) and anti-malarials to a wide range of eligible customers in the Least Developed Countries and sub-Saharan Africa; investment in research and development (R&D) that targets diseases that particularly affect the developing world; and community investment activities and partnerships that foster effective healthcare....
View Full Document

This note was uploaded on 10/24/2011 for the course MGMT 600 taught by Professor Dr.pal during the Spring '11 term at St. Johns Duplicate.

Page1 / 14

facing_the_challenge_one_year_on - FACING THE CHALLENGE ONE...

This preview shows document pages 1 - 6. Sign up to view the full document.

View Full Document Right Arrow Icon
Ask a homework question - tutors are online